Levodopa has been demonstrated to be an effective medication for Parkinson's disease (PD), but its long-term use is complicated by the subsequent development of dyskinesias. Few studies have distinguished distinct PD subtypes associated with the occurrence of Levodopa-Induced Dyskinesia (LID). Therefore, we performed a retrospective analysis to determine if the specific phenotype of PD and other epidemiological factors are associated with the development of LID. Of 367 PD patients taking levodopa, 101 of them developed LID. Multivariate logistic regression analysis demonstrated that initial tremor-dominant manifestation was associated with a reduced risk of LID, independent of other risk factors, such as age at the onset of PD, the duration and dose of levodopa.